Global Pediatric Epilepsy Therapeutics Market Report By Disease Type (Benign Rolandic Epilepsy (BRE), Childhood Absence Epilepsy (CAE), Juvenile Myoclonic Epilepsy (JME), Infantile Spasms (or West syndrome), Lennox-gastaut Syndrome (LGS), Others), By Therapeutics (Anti-Epileptic Drugs, Dietary Supplements, Vagal Nerve Stimulation, Surgical Therapies, Focal Cortical Resection, Lobectomy, Corpus Callosotomy, Hemispherectomy), By End User (Hospitals, Neurology Centers, Home Care Settings, Ambulatory Surgical Centers) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2022-2030
The global demand for Pediatric Epilepsy Therapeutics Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period of 2022 - 2028.
Pediatric epilepsy is the most common and challenging neurologic disorders. Various modalities exist to treat pediatric-onset seizures. It can be treated with anticonvulsant medications, a ketogenic diet, and a vagal nerve stimulator. Young infants with intractable epilepsy are candidates for surgery. Surgical procedures include removing a circumscribed portion of the temporal lobe, hemispherectomy, lobectomy corpus, and callosotomy. With a new resurgence in ubiquity and extension of signs, these treatments can prompt independence from seizures or an altogether decreased seizure trouble for some patients.
The growing frequency of epilepsy among children, rising awareness regarding treatment, and increasing approval for new drugs and devices for treatment drive the global pediatric epilepsy therapeutics market. As per the National Center for Biotechnology Information, the incidence of pediatric epilepsy ranges from 41-187 per 100,000. The higher rate is reported from rural areas of underdeveloped countries. The market is witnessing many changes in terms of treatment. There has been a wave of new approvals in recent years. Researchers are actively examining new medications and non-drug treatments for epilepsy. New types of neuromodulator devices have been approved to treat epilepsy. Despite the development of new epilepsy treatments, approximately one-third of pediatric patients with epilepsy remain medically refractory due to lack of awareness, high expenses, and fear of unacceptable side effects. Companies are engaged in tackling these challenges. Successful overcome of this will result in fruitful revenue.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each segment in the global market of pediatric epilepsy therapeutics.
This section of the pediatric epilepsy therapeutics market report provides detailed data on the segments by analyzing them geographically, thereby assisting the strategist in identifying the target demographics for the respective product or service.
By Disease Type
Benign Rolandic Epilepsy (BRE)
Childhood Absence Epilepsy (CAE)
Juvenile Myoclonic Epilepsy (JME)
Infantile Spasms (Or West Syndrome)
Lennox-Gastaut Syndrome (LGS)
Vagal Nerve Stimulation
Focal Cortical Resection
By End User
Home Care Settings
Ambulatory Surgical Centers
This section covers regional segmentation which accentuates on current and future demand for Pediatric Epilepsy Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Pediatric Epilepsy Therapeutics Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the pediatric epilepsy therapeutics market include Abbott Laboratories, GlaxoSmithKline plc, Cephalon, Inc., Johnson & Johnson, Pfizer, Inc., Novartis AG, Sunovion Pharmaceuticals sInc., Valeant Pharmaceuticals International, Inc., and Sanofi S.A. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
1 . PREFACE
1.1. Report Description
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . PEDIATRIC EPILEPSY THERAPEUTICS – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 By Disease Type
3.7.2 By Therapeutics
3.7.3 By End User
3.7.4 By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
5.1. Impact Analysis of Covid-19 Outbreak
5.1.1. Direct Impact on Production
5.1.2. Supply Chain and Market Disruption
5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand